In this episode, Ali Abdalbari from the University of Ottawa's Translational and Molecular Medicine (TMM) program speaks with Dr. Morgan Fullerton, Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. This episode features a discussion surrounding Dr. Fullerton’s most recent paper, published in the Atherosclerosis Journal (https://doi.org/10.1016/j.atherosclerosis.2024.117608). Dr. Fullerton provides an in-depth overview of his team’s discoveries and offers his expertise in the field of metabolic research, highlighting the importance of model systems of disease and the implications of his research in this field.

Learn more: https://doi.org/10.1016/j.atherosclerosis.2024.117608

Fullerton Lab: https://www.fullertonlab.com/

0:10 | BEaTS and host introduction
0:39 | Introduction to Dr. Fullerton
1:39 | Podcast topic introduction
1:56 | Guest welcome
2:08 | Introduction to atherosclerosis
3:44 | Focus of the Fullerton lab: metabolism and AMPK
6:32 | Interlude: a study from collaborator Dr. Kim Loh
7:04 | Concept of “negative data”
7:43 | Data and challenges
10:16 | Impact of research on the field of atherosclerosis
11:33 | Accessibility and efficient communication in science
13:23 | Podcast Outro

Soundtrack by the Underground Drive. All rights reserved. Listen more:
https://music.apple.com/ca/artist/the-underground-drive/1571062779
https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmR

Podcast credits: Ali Abdalbari (Show Host), Brianna Kore (Audio Master), Michelle Levesque (Writer Editor), Peter Noel (Producer).

Matteus McCulloch from the University of Ottawa interviews Dr. Michele Ardolino, a senior scientist in cancer research at the Ottawa Hospital Research Institute and an Assistant Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. In this episode, Dr. Ardolino discusses a recent paper published by his lab about PD-L1 and its inhibition of the Type I IFN pathway during oncolytic virus infection, how the research came about, and the relevance of the work to advance cancer treatment. 

Learn more about Dr. Ardolino and the work of the Ardolino Lab:
https://www.uottawa.ca/faculty-medicine/dr-michele-ardolino
https://ardolinolab.ca/

0:00 | Introduction to PD-L1 and the type I IFN pathway and its relevance to recent research by Hodgins, J.J. et al.
1:40 | BEaTS, host, and guest introduction
2:18 | What inspired the Ardolino Lab's exploration of PD-L1 and the type I IFN pathway?
5:01 | What setbacks were encountered over the course of this study?
6:35 | What is the mechanism of action for PD-L1 antibodies and oncolytic viruses in cancer therapy?
8:17 | Clinical applications of PD-L1 antibodies and oncolytic viruses for cancer therapy
9:50 | Impactful moments during the research process
10:57 | Next steps in PD-L1 research
12:02 | Advice for students entering research
13:30 | End credits

This podcast features the following songs:
"Hidden Realm" by I.V.Lab, available under a Creative Commons Attribution-NonCommercial license.
Listen here: https://archive.org/details/ffs62
"600 light years" by Macroform, available under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 license.
Listen here: https://archive.org/details/Macroform2011

Matteus McCulloch (Podcast Host), Serena Bezanson (Script Writer), Sara Ladha (Audio post-production), Mattheuren Aucoin (Producer).

Anastasia Fahlman and Sarah Damiani from the University of Ottawa speak with Dr. Erin Mulvihill, Scientist and Director of the Energy Substrate Metabolism Research Laboratory at the University of Ottawa Heart Institute. Tune in to learn more about her recent work published in CellPress, which explores the potential mechanisms underlying the cardioprotective benefits of metabolic surgery and GLP-1RA-based therapies. It also discusses recent evidence and emerging therapies in this dynamic area of research.

Learn more: https://www.sciencedirect.com/science/article/pii/S1043276024001930                                                                     

Credits for music: Soundtracks by the Underground Drive. All rights reserved. Listen more:

https://music.apple.com/ca/artist/the-underground-drive/1571062779

https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmR

Podcast by Sarah Damiani (Voice, Producer, Show Co-Host, Writer Editor, Audio Master) and Anastasia Fahlman (Voice, Show Co-Host, Writer Editor, Audio Master)

Maryam Yassin from the University of Ottawa interviews Dr. Anna Jezierski and Dr. Alex MacKenzie. Dr. Jezierski is a research officer at the Department of Translational Biosciences in the Human Health Therapeutics Research Center at the National Research Council of Canada. She is also an adjunct professor for the Department of Biochemistry, Microbiology, and Immunology at the University of Ottawa. In this episode, Dr. Jezierski shares her research on modeling the human blood-brain barrier using induced pluripotent stem cells and the various applications of this model in studying therapeutics for diseases of the central nervous system. We're also joined by Dr. Alex Mackenzie, an attending pediatrician and senior scientist at the Children's Hospital of Eastern Ontario (CHEO). He has served as the CEO and Scientific Director of CHEO Research Institute and is a cross-appointed member of the Faculty of Medicine at the University of Ottawa. Dr. Mackenzie comments on how this model is revolutionizing drug development.


Learn more:  https://www.uottawa.ca/faculty-medicine/dr-anna-jezierski
https://www.cheoresearch.ca/research/find-a-researcher/alex-mackenzie/

0.03 | BEaTS and host introduction.
0.26 | Introduction to Dr. Jezierski.
1.17 | Introduction to Blood-Brain Barrier (BBB).
3.22 | Creating a BBB model using induced pluripotent stem cells is important.
7.07 | How tight junctions are replicated effectively.
9.20 | Applications of the iPSC-derived BBB model.
12.35 | Introduction to Dr. Alex Mackenzie
12.51 | Implications of the model on drug discovery and clinical trials.
14.54 | Closing remarks.

Soundtracks by the Underground Drive. All rights reserved. Listen more
https://www.dropbox.com/scl/fo/yrgjajtxzy4j08zj5iptc/AF7HMueoQwogLQMFxHxSHpU?e=1&preview=BEaTS+-+music+only+2.wav&rlkey=epcpj63eohwgi44mnqg7ctoa6&st=bn1v69ik&dl=0

Maryam Yassin (Voice), Aysha Aftab (Post-Production), Dalia Zeidan (Content Generation), Jordan Yin (Producer). 

Join Kahliana Nguyen and Khaled Najjar, Translational and Molecular Medicine students, as they speak with Dr. Baptiste Lacoste, a neuroscience researcher at the Ottawa Hospital Research Institute whose recent work focuses on the critical role of the brain’s vascular system in development. 

The episode explores a new perspective on autism spectrum disorders (ASD) and how problems with the brain’s blood vessels in early development may contribute to challenges seen in autism. Dr. Lacoste goes into depth on how these blood vessels play a role in brain growth, energy use, and behavior. By studying these interactions alongside neural and genetic factors, his research opens new avenues in how we understand autism and find better ways to address ASD. Whether you’re a researcher, student, or simply curious, this episode offers an exciting new lens to the field.

Learn more: Dr Baptiste Lacoste

Dr Baptiste Lacoste | Faculté de médecine

https://bsky.app/profile/blacoste.bsky.social

https://www.ohri.ca/profile/lacostelab

0:02 | BEaTS and host introduction.
0:22 | Introduction to Dr. Lacoste
1:10 | Why did Dr. Lacoste choose to focus on the vascular system specifically?
3:05 | The Neurovascular unit (NVU) and its importance in Dr. Lacoste's research on ASD
5:15 | The use of mice with a 16p11.2 deletion mutation to study ASD
8:43 | The novel findings were seen in Dr. Lactoste's lab study on ASD
10:51 | Treatment Strategies when it comes to ASD
12:03 | Limitations & Challenges Dr. Lacoste's lab faced and still faces while studying ASD
13:50 | Wrapping up the episode

Science and Innovation by Vicate. All rights reserved. Listen more:
https://www.jamendo.com/album/578641/science-and-innovation
Vicate | Jamendo Music | Free music downloads

Kahliana Nguyen (Voice) & Khaled Najjar (Producer & Editor)

Lia Morton from the University of Ottawa interviews Dr. Marisa Azad. Dr. Azad is a physician-scientist at the Ottawa Hospital Research Institute and an Assistant Professor of medicine in the division of infectious diseases at the University of Ottawa. In this episode, Dr. Azad shares her insight and expertise on implant-associated infections (IAIs), notably the challenges of detecting and diagnosing IAIs and emerging diagnostic methods.

Learn more: https://www.ohri.ca/newsroom/story/view/1543?l=en   

0:00 | BEaTS and host introduction.
0:38 | Introduction to Implant-Associated Infections (IAIs)
1:40 | Introduction to Dr.Azad.
2:11 | Why is IAI diagnosis so difficult, and what makes it particularly challenging?
3:39 | Implant types that are notably hard to detect.
4:29 | How do biofilms contribute to the formation of IAIs, and what makes them dangerous?
7:41 | Limitations associated with microbiological analyses.
11:09 |Future work and new approaches considered to identify IAIs.
12:59 |The diagnostic methods currently being used in the clinic
14:26 | Farewells and closure.

Soundtrack by The Underground Drive. Song Titled: BEaTS. All rights reserved.

https://music.apple.com/ca/artist/the-underground-drive/1571062779

https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmR

Lia Morton (Show Host, Content Generation), Julianne Morin (Production, Content Generation),  Amal Assebbane (Script, Content Generation), Adjia Seynabou Sy Gueye (Post-Production, Content Generation)

Maheen Khanotia from the Translational Molecular Medicine program interviews Dr. Barabara Vanderhyden, a distinguished researcher at the Ottawa Hospital and a professor at the University of Ottawa. She is a leading researcher in ovarian cancer, focusing on the BRCA1 and BRCA2 mutations. In this podcast, Maheen discusses with Dr. Vanderhyden her key findings in her 2023 paper "BRCA1 and BRCA2 deficient tumor models generate distinct ovarian tumor microenvironments and differential responses to therapy," where they delve into the world of cancer, Dr. Vanderhyden's lab findings, potential treatments, and research advice.

Learn more:  https://www.ohri.ca/profile/vanderhydenlab/profile

0:05 | BEaTS and host introduction.
1:17 | Introduction to Dr. Barbara Vanderhyden.
1:39 | How did you come to study ovarian cancer?
2:48 | What led you to believe the BRCA1 and BRCA2 mutations are different?
3:50 | What is the tumor microenvironment?
4:57 |  What do the research findings mean to the general public?
6:05 | Why do BRCA1 and BRCA2 deletions at the gene and protein levels have different effects on tumor microenvironments?
8:04 | What were the challenges you went through as a researcher?
9:18  | What were the crucial limitations of your research?
10:24  | What are the future steps for ovarian cancer research?
11:56  | What is general advice you would give to other researchers?
12:55  | How long does a study like this take?
13:40  | How does this research affect a patient's diagnosis?
14:31  | Closing remarks

Credits for music: Soundtracks by the Underground Drive. All rights reserved. Listen more

https://music.apple.com/ca/artist/the-underground-drive/1571062779

https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmR

Maheen Khanotia (Voice, host, editor), Soniya Agarwal (Producer, writer)

In this episode, Celina Tanbari from the University of Ottawa interviews Dr. Adam Rudner about the fascinating world of bacteriophages—viruses that target and kill bacteria. Dr. Rudner is the coordinator of the University of Ottawa’s Phage Hunters program, a member of the SEA-PHAGES and SEA-GENES programs, and an Associate Professor in the Department of Biochemistry, Microbiology, and Immunology. Dr. Rudner shares with us his expert opinion on a study that isolated bacteriophages from human skin to kill infection-causing bacteria. The discussion delves into the therapeutic potential of phages, their involvement in biofilms and lysogeny, and the challenges associated with utilizing phages in medicine.

This episode was produced and written by Emma Etchells Foisy, hosted by Celina Tanbari, and audio edited by Sam Rogers. Copyrights are reserved to BEaTS Research Radio and the University of Ottawa.

If you are interested in learning more about the paper we discussed today, you can find it through the following link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10117716/

Learn more: https://www.uottawa.ca/faculty-medicine/dr-adam-rudner

0:03 | BEaTS and host introduction.
0:38 | Introducing Dr. Rudner.
1:05 | What are bacteriophages?
1:41 | Phages as a possible solution to antibiotic-resistant bacteria
2:41 | What are biofilms, and how do they affect bacterial infections?
5:01 | Phage BE01 and how lysogeny can affect phage therapy.
8:52 | Phage BE04 and the potential of phages in replacing antibiotics.
10:55 | Squashing the stigma, phages only attack bacteria.
12:35 | Potential challenges with phage therapy.
14:08 | Dr. Rudner's take-home message.
14:36 | Thank yous and credits!

Soundtrack, Chillout by AudioCoffee | https://www.audiocoffee.net/
Music promoted by https://www.chosic.com/free-music/all/
Creative Commons CC BY-SA 3.0
https://creativecommons.org/licenses/by-sa/3.0/

A series of interviews with presenters and participants at the Music and Health Research Institute's annual conference at The Royal Ottawa Mental Health Centre. This episode serves as an introduction to the ongoing work of institute members in the field of Music and Health research and practice. 

Lucas Marchand (Interviewer, Post-production, Content generation, Producer)

Learn more: https://www.uottawa.ca/research-innovation/music-health

0:02 | Host introduction.
0:29 | Interview with Dr. Jane Gosine of Memorial University
2:15 | Interveiw with Ludovic Dubé
4:34 | Interview with Dr. Chi Lo of Singwell
9:45 | Interview with Dr. Erin Parks of Lotus Centre
14:15 | Interview with Cory Butler of Zamar Music


Original music written and recorded by Lucas Marchand 

Deyanira Hernandez de la Universidad de Ottawa, habla con la Dra. Daniela Gordillo Bastidas, Directora Nacional del programa de Nutrición y Bienestar Integral del Tecnológico de Monterrey. En este episodio se abordan temas relacionados con medicamentos en el tratamiento de diabetes y diminución de peso, así como posibles efectos secundarios y criterios de evaluación para su prescripción.

Acerca del Tecnológico de Monterrey: https://tec.mx/en

1:39 -  El medicamento Ozempic originalmente se desarrolló como un medicamento para la diabetes tipo 2, sin embargo, ha ganado mucha popularidad en los últimos años, especialmente por su uso en la pérdida de peso. ¿Podría explicarle a nuestra audiencia cómo es que este tipo de medicamentos actúan en nuestro cuerpo?
5:45 - ¿Qué consideraciones debería de tener en cuenta el personal de salud antes de prescribir este medicamento y cuáles podrían ser efectos secundarios de su uso?
10:38 - En su experiencia, ¿cómo considera que se puede integrar a medicamentos como lo es ozempic en el tratamiento de pacientes que cumplan con los requisitos de su prescripción? ¿Es la medicación un sustituto o un complemento en el manejo del peso?